| (Values in U.S. Thousands) | Mar, 2018 | Dec, 2017 | Sep, 2017 | Jun, 2017 | Mar, 2017 |
| Sales | 0 | 110 | 320 | 320 | 320 |
| Sales Growth | -100.00% | -65.63% | unch | unch | unch |
| Net Income | -10,360 | -5,920 | 9,420 | -8,150 | -18,560 |
| Net Income Growth | -75.00% | -162.85% | +215.58% | +56.09% | -663.79% |
Steadymed Ltd Ord Sh (STDY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
SteadyMed Ltd. is a specialty pharmaceutical company which focused on the development of drug products to treat orphan and other diseases. The company's lead candidate consist of Trevyent(R), a development stage drug product which utilizes SteadyMed's PatchPump(R) technology to treat pulmonary arterial hypertension. SteadyMed Ltd. is headquartered in San Ramon, California.
Fiscal Year End Date: 12/31